1. Home
  2. BLZE vs FHTX Comparison

BLZE vs FHTX Comparison

Compare BLZE & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Backblaze Inc.

BLZE

Backblaze Inc.

HOLD

Current Price

$4.85

Market Cap

282.6M

Sector

Technology

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.79

Market Cap

247.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLZE
FHTX
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.6M
247.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BLZE
FHTX
Price
$4.85
$5.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$9.50
$11.43
AVG Volume (30 Days)
872.7K
168.3K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$141,859,000.00
$24,518,000.00
Revenue This Year
$16.43
$47.50
Revenue Next Year
$11.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.73
N/A
52 Week Low
$3.94
$2.95
52 Week High
$10.86
$6.79

Technical Indicators

Market Signals
Indicator
BLZE
FHTX
Relative Strength Index (RSI) 40.05 74.06
Support Level $4.44 $4.21
Resistance Level $5.09 $4.59
Average True Range (ATR) 0.21 0.32
MACD 0.15 0.12
Stochastic Oscillator 61.19 90.52

Price Performance

Historical Comparison
BLZE
FHTX

About BLZE Backblaze Inc.

Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: